- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/55 - IL-2
Patent holdings for IPC class C07K 14/55
Total number of patents in this class: 1626
10-year publication summary
|
37
|
50
|
80
|
125
|
139
|
235
|
218
|
213
|
213
|
112
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Cue Biopharma, Inc. | 190 |
63 |
| The Board of Trustees of the Leland Stanford Junior University | 6416 |
43 |
| Immunitybio, Inc. | 372 |
27 |
| Hoffmann-La Roche Inc. | 3422 |
26 |
| Amgen Inc. | 4044 |
25 |
| Cancer Research Technology Limited | 523 |
25 |
| Tusk Therapeutics Ltd | 31 |
25 |
| Regeneron Pharmaceuticals, Inc. | 4253 |
21 |
| F. Hoffmann-La Roche AG | 7921 |
20 |
| GI Innovation, Inc. | 51 |
20 |
| Medicenna Therapeutics Inc. | 38 |
19 |
| University of Washington | 2330 |
19 |
| Werewolf Therapeutics, Inc. | 54 |
19 |
| Deka Biosciences, Inc. | 43 |
19 |
| Xilio Development, Inc. | 44 |
19 |
| Delinia, Inc. | 43 |
18 |
| Pandion Operations, Inc. | 35 |
17 |
| Askgene Pharma, Inc. | 49 |
15 |
| Roche Glycart AG | 140 |
15 |
| Anwita Biosciences, Inc. | 27 |
14 |
| Other owners | 1157 |